Showing results (191-200 of 217) with videos related to
Sort By:
Pageof 22
Cancer Medicine|December 17, 2025
Prognostic Stratification of Initial Treatments for Hepatocellular Carcinoma Using a Modified Borderline Resectable ClassificationFujimasa Tada, Atsushi Hiraoka, Hideko Ohama, et al.Bioorganic & Medicinal Chemistry Letters|September 17, 2016
Discovery of novel 2',4'-dimethyl-[4,5'-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: Part 2Naoki Tsuno, Akira Yukimasa, Osamu Yoshida, et al.Euroasian Journal of Hepato-Gastroenterology|January 13, 2025
HeberNasvac: Development and Application in the Context of Chronic Hepatitis BJulio C Aguilar, Sheikh Mf Akbar, Mamun Al-Mahtab, et al.Clinical Journal of Gastroenterology|March 26, 2024
Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapyFujimasa Tada, Atsushi Hiraoka, Kosuke Nakatani, et al.Clinical Nutrition ESPEN|July 17, 2025
Early alterations in nutritional indices in metabolic dysfunction-associated steatotic liver disease-related cirrhosisTeruki Miyake, Shinya Furukawa, Osamu Yoshida, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 22, 2025
Dynamic changes in the characteristics of hepatocellular carcinoma among Japanese patients: Increasing incidence of cases without liver fibrosisFujimasa Tada, Atsushi Hiraoka, Hideko Ohama, et al.Journal of Gastroenterology and Hepatology|April 18, 2024
Changes in characteristics of gastroenterology center inpatients in Japan because of rapidly aging societyYoshiko Fukunishi, Atsushi Hiraoka, Fujimasa Tada, et al.Journal of Medicinal Chemistry|January 6, 2023
Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an In Vivo Model of Trypanosoma cruzi InfectionTaisuke Tawaraishi, Atsuko Ochida, Yuichiro Akao, et al.Journal of Gastroenterology and Hepatology|January 23, 2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCCTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.Oncology|February 3, 2025
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not SufficientAtsushi Hiraoka, Masatoshi Kudo, Toshifumi Tada, et al.Pageof 22